Hoikoleu Tablets 100 mg (Camostat Mesilate)

Adult dose

○ Chronic pancreatitis Adults: Administer 200mg of camostat mesilate per dose orally 3 times daily. ○ Reflux esophagitis after gastrectomy Adults: Administer 100mg of this drug per dose 3 times daily. Adjust the dose appropriately according to symptoms.

This medication should not be used in patients with severe conditions that require dietary restrictions such as gastric juice suction, fasting, or restriction of oral intake. Furthermore, the effect of this medication is not expected in patients with gastroesophageal reflux disease that occurs postoperatively due to gastric juice regurgitation, and it should not be administered. This medication contains lactose; therefore, it should not be administered to patients with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. It should be used with caution in pregnant women or women of childbearing age, children, and the elderly. During the use of this medication, eosinophilia or rarely leukopenia and thrombocytopenia may be observed in blood tests; if such symptoms appear, the dosage should be reduced or the administration should be discontinued. In addition, hypersensitivity reactions such as skin rash or itching may occasionally occur; if these symptoms occur, administration should be discontinued immediately. Gastrointestinal symptoms may include loss of appetite, nausea, dry mouth, abdominal pain, abdominal discomfort, abdominal distension, diarrhea, and rarely vomiting, heartburn, and constipation. There may be an increase in liver function test values or liver dysfunction, requiring caution. Regarding kidney function, blood levels of BUN and creatinine may rarely increase. Additionally, edema may occur, or rarely hypoglycemia and hyperkalemia may appear, so the patient’s condition should be monitored. If symptoms do not improve, it is advisable not to use this medication for an extended period. High-dose administration should be avoided in pregnant women as fetal weight reduction has been reported in animal studies. There is insufficient experience regarding the safety of this medication in children, especially in low birth weight neonates or infants. The elderly may experience more severe adverse reactions, so caution is warranted. Lastly, this medication should be stored and dispensed separately from Olmesartan Medoxomil formulations to prevent discoloration.

• Eosinophilia
• leukopenia
• thrombocytopenia
• rash
• itching
• loss of appetite
• nausea
• dry mouth
• abdominal pain
• abdominal discomfort

This medication should be stored in a tightly closed container to prevent air or moisture ingress, ideally at temperatures between 1 and 30 degrees Celsius at room temperature. Storing it this way will help maintain the efficacy of the medication and ensure safe use.

Appearance

White or yellowish round film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle